Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00042302
Status:
TERMINATED
Last Update Posted:
2012-05-23
First Post:
2002-07-26
Brief Title:
A Double-Blind Randomized Placebo-Controlled Multicenter Phase III Study of Tariquidar PaclitaxelCarboplatin as First-Line Therapy in Non-Small Cell Lung Cancer NSCLC
Sponsor:
QLT Inc
Organization:
QLT Inc
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine whether tariquidar combined first-line chemotherapy of paclitaxelcarboplatin in patients with Stage IIIbIV NSCLC will with an acceptable safety profile significantly improve overall survival compared with placebo paclitaxelcarboplatin To compare the effects of tariquidarpaclitaxelcarboplatin with placebopaclitaxelcarboplatin on tumor response time to disease progression performance status symptom progression and quality of life in patients with Stage IIIbIV NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None